Lumiliximab is a chimeric macaque-human monoclonal antibody to CD23, a protein expressed on virtually all chronic lymphocytic leukemia (CLL) cells. We examined the ability of lumiliximab to mediate apoptosis, antibody-dependent cellular cytotoxicity, and complement-dependent cytotoxicity against primary CLL cells and CD23-expressing Bcell lines. Our data suggest that lumiliximab kills CLL cells and CD23-expressing B cells predominantly by apoptosis that occurs through the intrinsic pathway. Lumiliximabinduced apoptosis was accompanied by the downregulation of anti-apoptotic proteins Bcl-2, Bcl-X L , and XIAP, activation of Bax, and release of cytochrome c from the mitochondria. We also found that the addition of lumiliximab to rituximab or fludarabine results in synergistic cytotoxicity of primary CLL cells and CD23-expressing B-cell lines.
5 the survival of germinal center B cells. 20 The expression of CD23 is highly upregulated in normal activated follicular B cells and in CLL B cells. [21] [22] [23] Lumiliximab is a primatized monoclonal anti-CD23 antibody that contains cynomolgus macaque variable regions and human constant regions (IgG1, κ ) 24 that was developed to inhibit the production of IgE by activated human peripheral blood B cells. 25, 26 In studies in allergic rhinitis and asthma lumiliximab had minimal toxicity but modest efficacy. 27 Because of the broad expression of CD23 in CLL and the success with other B-cellselective antibodies such as rituximab and alemtuzumab in CLL, we sought to investigate whether lumiliximab could promote killing of primary CLL cells and related CD23+
transformed B-cell lines by initiating apoptosis, antibody-dependent cellular cytotoxicity
Antibodies and chemicals
Lumiliximab is a chimeric macaque-human monoclonal antibody to human CD23 that contains human γ1 heavy chains and human κ light chains. 24 Rituximab is a chimeric mouse-human γ1/κ antibody to human CD20. 29 CE9.1 is a chimeric macaque-human antibody to human CD4 with human γ1 heavy chains and human κ light chains that is Pharmaceutical-grade fludarabine (Fludara; Berlex Laboratories, Richmond, CA) was prepared as recommended by the supplier.
Cell treatment
CLL cells (1 × 10 6 cells/mL) or SKW6.4 cells (0.5 × 10 6 cells/mL) were incubated with lumiliximab or rituximab (0.01 µg/mL to 10 µg/mL) in assay medium (RPMI 1640 supplemented with 5% fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin) for 1 hour on ice. Cells were centrifuged, resuspended in assay
For personal use only. on April 16, 2017. by guest www.bloodjournal.org From medium, incubated in the presence of F(ab′) 2 goat antihuman IgG Fc γ chain-specific antibodies (15 µg/mL), and incubated in for 18 hours at 37°C. The different parameters for cell treatment were independently optimized. In the combination studies, lumiliximab and rituximab were added together or fludarabine was added when the secondary crosslinking antibody was added.
Apoptosis assays
Apoptosis was assessed by using a flow cytometry-based caspase-3 assay. Cultured cells were harvested, washed, and fixed on ice in Cytofix (Cytofix/Cytoperm Kit, BD Pharmingen) according to the manufacturer's instructions. Flow cytometry data were acquired on a FACScan (BD Biosciences, San Jose, CA) and were analyzed by using
WinList software (Verity Software House, Topsham, ME) or on a FACSCalibur (BD Biosciences) and analyzed by using CellQuest software (BD Biosciences).
For caspase inhibitor experiments, CLL cells were pre-incubated with 100 µM caspase inhibitor or dimethyl sulfoxide (DMSO) control for 30 minutes at 37°C, before treatment.
After incubation and washing to remove unbound primary antibody, 100 µM caspase inhibitor was re-added to the assay medium containing the secondary cross-linking antibody. Apoptosis was then measured by staining with annexin V. For annexin V assays, the detection of phosphatidylserine exposure was assessed by double-staining cells with fluorescein isothiocyanate-labeled annexin V and propidium iodide (Roche Biosciences, Palo Alto, CA). Flow cytometry data were acquired and analyzed as described above. Apoptotic cells were defined as the percentage of annexin V-positive/propidium iodide-negative cells.
ADCC assays
ADCC activity was determined by standard 4-hour chromium 51-release assays. 51 
Western blot analysis
Cell lysates were prepared in RIPA lysis buffer: 10 mM Tris (pH 7.4), 150 mM NaCl, 1%
Triton X-100, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate, 5 mM EDTA and protease inhibitors. The amount of protein in each clarified lysate was quantified by using the bicinchoninic acid method (Pierce, Rockford, IL). Each sample was normalized for total protein content (12.5 µg/lane) and was subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis (12% polyacrylamide gel) followed by transfer to 
Immunocytochemistry.
Isotype control or lumiliximab-treated CLL cells were deposited onto Biocoat 
Subcellular fractionation
For personal use only. on April 16, 2017. by guest www.bloodjournal.org From Cells were fractionated by digitonin lysis, as described by Heibein et al. 30 Cells were treated briefly with medium alone or lumiliximab, washed once in ice-cold PBS, and resuspended in 200 µL 0.025% digitonin for 5 minutes on ice. Samples were centrifuged for 5 minutes at 20,800g at 4°C, and supernatant (cytosol) and pellet (membrane)
fractions collected for Western analysis.
Tumor model
A disseminated human lymphoma model in SCID mice was used for in vivo evaluation of antibody therapy. SKW6.4 cells (between 3 × 10 6 and 4 × 10 6 ) were intravenously injected into the tail veins of 6-to 8-week-old female SCID mice (10 mice per group).
Mice in the single-agent treatment groups were given 100 µg, 200 µg, or 400 µg lumiliximab or rituximab. Mice in the combination-agent group were given 200 µg each of lumiliximab and rituximab. All antibodies were injected intraperitoneally in a final volume of 200 µL. Mice in the control group were given 400 µg of CE9.1 (isotype control for lumiliximab) in the same formulation buffer and volume as lumiliximab and rituximab. The antibody injections were given on days 1, 3, 5, 7, 9, and 11 or on days 3, 7, 11, and 15 after tumor inoculation. The doses were based on a minimum half-life of human IgG1 antibodies in SCID mice of 3 days, and were calculated to achieve a steadystate trough level of 100 to 300 µg/mL on day 14. Fludarabine (50 mg/kg) was injected on days 5 and 10. A paralytic form of disseminated lymphoma developed in all of the mice before they died. Mice were monitored for the development of the disease and death. Mice that died between observation periods or in which full paralysis or labored breathing developed were euthanized and scored as dead.
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Results

Lumiliximab mediates apoptosis of CLL and CD23+ transformed lymphoma cells
To test the ability of lumiliximab to induce apoptosis, CLL cells from 16 patients and a variety of lymphoma cell lines were incubated in the presence of lumiliximab or control antibody, followed by cross-linking with goat antihuman IgG antibody.
Apoptosis was assessed 18 hours later by using a flow cytometry-based assay that measures activated caspase-3, a marker for cells undergoing apoptosis. Treating 
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To determine if Bax activation at mitochondria was accompanied by release of cytochrome c, subcellular fractionation studies were performed as described in "Materials and methods." Release of cytochrome c was detected by Western analysis in the cytosol of CLL cells treated for 2 hours with lumiliximab but not in cells treated with isotype control antibody ( Figure 4C ). Antibodies to Rho-GD1 and VDAC were used as markers for cytosolic and membrane fractions, respectively (data not shown). These data indicate that cytochrome c translocates from the membrane fraction to the cytosol after lumiliximab treatment.
Lumiliximab-induced apoptosis was reversed by caspase inhibitors
To investigate if the lumiliximab-induced apoptosis can be reversed using caspase inhibitors, CLL cells were treated with lumiliximab in the presence of the pan caspase inhibitor z-VAD-fmk. On average, in the presence of z-VAD-fmk and z-LEHD-fmk, lumiliximab-induced apoptosis was reduced to 51% and 54% of maximal apoptosis, respectively ( Figure 4D ). The caspase-inhibitory activity of the z-VAD-fmk and z-LEHD-fmk used in these experiments was confirmed in control experiments in which both inhibitors completely blocked lumiliximab-induced caspase-9 activation ( Figure   4E ). The results from these caspase inhibitor experiments support the hypothesis that lumiliximab induces apoptosis in a caspase-dependent manner.
Lumiliximab induces changes in the expression of anti-apoptotic regulatory proteins.
For
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In light of data implicating the role of the mitochondrial pathway in lumiliximab-induced apoptosis, the ability of lumiliximab to modulate the expression of proteins that regulate the release of mitochondrial proteins was investigated. Western analyses revealed that lumiliximab induced the downregulation of anti-apoptotic proteins Bcl-2, Mcl-1 and XIAP. In contrast, the expression of a number of other anti-apoptotic proteins, including cIAP-1, cIAP-2 and survivin, did not change following lumiliximab treatment in CLL cells ( Figure 5 ). Pro-apoptotic Bcl-2 proteins also were examined; however, no significant changes in the levels of Bax, Bid, Bik, and Bad were observed (data not shown).
Lumiliximab enhances apoptosis mediated by rituximab and fludarabine
Because lumiliximab strongly induced apoptosis, we hypothesized that this agent might also add to the effectiveness of other agents that are used in treating CLL. Combinations Figure 6D ). This suggests that lumiliximab may synergize with rituximab and fludarabine to induce apoptosis in CD23-expressing cells, including CLL cells.
In vivo anti-tumor activity of lumiliximab as a single agent or in combination with rituximab or fludarabine
There are at this time no good in vivo models for testing the efficacy of antibodies for the treatment of CLL. We therefore tested the in vivo anti-tumor effect of lumiliximab in a disseminated lymphoma SCID mouse model by using a cell line that expresses CD23. The mechanism by which apoptosis is induced by the ligation of membrane-bound CD23 by lumiliximab merits further investigation. Other therapeutic antibodies, such as rituximab, depend on intracellular signaling, likely through calcium-dependent pathways, to mediate apoptosis in transformed B-cells. In our in vitro studies we found that the induction of apoptosis by lumiliximab required cross-linking with a secondary antibody, similar to that required with both rituximab and alemtuzumab. This is also likely to occur in vivo, because lumiliximab bound to cell-surface CD23 is expected to be cross-linked The most important finding of our study is that lumiliximab has synergy both in vitro and in vivo with fludarabine and rituximab. Both of these agents are now used in the first-line treatment of CLL, and phase 2 studies have shown greater complete response rates and progression-free survival in patients treated with them than in historical controls who had been treated with older monotherapy for CLL. 13 A phase 1 trial of single-agent lumiliximab in CLL found that it lacked significant myelosuppression, immunosuppression, or toxicity that would preclude its being combined with rituximab or fludarabine. 38 Lumiliximab therapy is also associated with a relatively low rate of infusion reactions, 27 which may be a result of its lack of ADCC mediation. Developing a combination regimen of lumiliximab, fludarabine, and rituximab, therefore, seems rational. This strategy is supported by findings in the clinic. A recent multicenter doseescalation phase 1-2 study of lumiliximab combined with FCR (fludarabine,
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cyclophosphamide, and rituximab) for relapsed CD23+ B-cell CLL has shown promising results. 39 The study was conducted in 31 patients, 8 of whom had advanced-stage disease.
The overall response rate was 71% (complete response, 52%; partial response, 10%; and unconfirmed partial response, 10%). The 52% complete response rate compares favorably with the 25% complete response rate that was seen in a study conducted at the M. D. Anderson Cancer Center in 177 patients with relapsed or refractory CLL who were treated with FCR. 39 Safety was also similar in the two studies. The results of the current preclinical study also support combining lumiliximab with fludarabine or rituximab, or both. As the treatment of CLL moves toward combination regimens with both biologic and chemotherapy agents, lumiliximab may be a valuable addition to standard and novel therapies. 
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